Johnson & Johnson $JNJ is Brendel Financial Advisors LLC's 10th Largest Position

Key Points

• Brendel Financial Advisors LLC increased its holdings in Johnson & Johnson by 335.4% during the 2nd quarter, now owning 25,491 shares worth approximately $3.89 million.
• Johnson & Johnson reported $2.77 EPS for the last quarter, exceeding the forecast of $2.68, contributing to a quarterly revenue of $23.74 billion.
• The company announced a quarterly dividend of $1.30 per share, reflecting an annualized yield of 3.0% and a payout ratio of 55.61%.

Brendel Financial Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 335.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,491 shares of the company's stock after acquiring an additional 19,636 shares during the period. Johnson & Johnson makes up approximately 2.2% of Brendel Financial Advisors LLC's investment portfolio, making the stock its 10th largest position. Brendel Financial Advisors LLC's holdings in Johnson & Johnson were worth $3,894,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Lantz Financial LLC grew its stake in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares in the last quarter. Apexium Financial LP grew its stake in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after buying an additional 2,310 shares in the last quarter. Joel Isaacson & Co. LLC grew its stake in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its stake in Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after buying an additional 4,816 shares in the last quarter. Finally, Range Financial Group LLC grew its stake in Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 1.3%

Shares of NYSE JNJ traded up $2.19 during trading on Tuesday, hitting $176.40. The stock had a trading volume of 3,238,731 shares, compared to its average volume of 8,915,940. The firm has a fifty day moving average of $173.14 and a two-hundred day moving average of $161.69. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $424.82 billion, a PE ratio of 18.87, a PEG ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research note on Friday. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their price target for the company from $167.00 to $206.00 in a research note on Tuesday. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Finally, Bank of America raised their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.